Johnson & Johnson has received U.S. FDA approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform, an integrated catheter ablation solution for electrophysiology procedures.

The platform enables physicians to deliver both radiofrequency and pulsed field energy through a single catheter. It is integrated with Johnson & Johnson’s CARTO ecosystem, supporting mapping, imaging and guidance during cardiac ablation procedures.

The platform builds on the existing THERMOCOOL SMARTTOUCH SF catheter base, which Johnson & Johnson said has treated more than one million patients in the United States. The addition of pulsed field capability brings newer ablation modality options into a familiar catheter platform.

Pulsed field ablation has attracted strong interest because it may offer more tissue-selective energy delivery compared with traditional thermal approaches. Radiofrequency ablation remains widely used and clinically established. A dual-energy platform could therefore support physician choice while preserving procedural workflow continuity.

The system is integrated into the CARTO ecosystem, including advanced mapping, imaging and PF Index guidance. Johnson & Johnson said the integration supports energy delivery with contact force information and procedural reproducibility.

The commercial significance lies in workflow consolidation. Instead of using separate tools for RF and PF approaches, electrophysiologists may be able to adapt energy delivery strategy within the same procedure. This could be useful in complex cases where anatomy, lesion durability or procedural goals vary.

Following FDA approval, first U.S. procedures with the platform are expected to begin in summer 2026 as Johnson & Johnson initiates a phased commercial rollout.